Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...
Hosted on MSN16h
Hexaware Technologies IPO debuts strongly on NSEHexaware Technologies debuted positively on the National Stock Exchange (NSE) on Wednesday, listing shares at a 5.3% premium ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Lismore recorded 19 property sales over a million dollars last week, the latest auction and sales results reveal. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback